Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Search

Page Path
HOME > Search
1 "Michael Herzlinger"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
IBD
Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing
Rahiya Rehman, Muhammad Safwan Riaz, Dyadin Esharif, Phinnara Has, Michael Herzlinger, Jason Shapiro, Shova Subedi
Intest Res 2024;22(3):351-356.   Published online February 6, 2024
DOI: https://doi.org/10.5217/ir.2023.00091
AbstractAbstract PDFPubReaderePub
Background/Aims
To describe the role of ustekinumab in inducing remission and endoscopic healing in anti-tumor necrosis factor α nonresponsive pediatric ulcerative colitis patients at a tertiary care inflammatory bowel disease center.
Methods
A retrospective chart review was performed on patients with ulcerative colitis receiving ustekinumab. Primary outcome was steroidfree clinical remission at follow-up. Secondary outcomes were biochemical remission and endoscopic healing.
Results
Ten children were analyzed; 7 (70%) had ulcerative colitis, and 3 (30%) had inflammatory bowel disease unspecified with colitis. Median follow-up period was 56 weeks. Nine patients (90%) achieved steroid-free clinical remission and biochemical remission. Seven patients had follow-up colonoscopies, out of which 6 (86%) achieved endoscopic remission, while 1 (14%) underwent colectomy. Out of the 3 patients without a follow-up colonoscopy, fecal calprotectin levels downtrended to < 150 mg/kg in 2 patients and < 400 mg/kg in 1 patient from baseline level of > 2,000 mg/kg.
Conclusions
Ustekinumab appears efficacious in achieving not only clinical and biochemical remission but also has promising role in inducing endoscopic healing end point in patients who fail other biologics.

Citations

Citations to this article as recorded by  
  • Positionspapier der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE) zum zulassungsüberschreitenden Gebrauch von für Erwachsene mit CED zugelassenen Biologika und Signalinhibitoren bei Kindern und Jugendlichen
    Jan Däbritz, Martin Classen, Kathrin Krohn, Andreas Krahl, Stephan Buderus, Elke Lainka, Jan de Laffolie, Carsten Posovszky
    Zeitschrift für Gastroenterologie.2025; 63(03): 255.     CrossRef
  • New Therapeutic Challenges in Pediatric Gastroenterology: A Narrative Review
    Valeria Dipasquale, Claudio Romano
    Healthcare.2025; 13(8): 923.     CrossRef
  • Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress
    Debora Curci, Marianna Lucafò, Giuliana Decorti, Gabriele Stocco
    Expert Opinion on Biological Therapy.2024; 24(10): 1133.     CrossRef
  • 3,476 View
  • 286 Download
  • 2 Web of Science
  • 3 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP